Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

被引：0

作者：

Giulia Bon

Laura Pizzuti

Valentina Laquintana

Rossella Loria

Manuela Porru

Caterina Marchiò

Eriseld Krasniqi

Maddalena Barba

Marcello Maugeri-Saccà

Teresa Gamucci

Rossana Berardi

Lorenzo Livi

Corrado Ficorella

Clara Natoli

Enrico Cortesi

Daniele Generali

Nicla La Verde

Alessandra Cassano

Emilio Bria

Luca Moscetti

Andrea Michelotti

Vincenzo Adamo

Claudio Zamagni

Giuseppe Tonini

Giacomo Barchiesi

Marco Mazzotta

Daniele Marinelli

Silverio Tomao

Paolo Marchetti

Maria Rosaria Valerio

Rosanna Mirabelli

Antonio Russo

Maria Agnese Fabbri

Nicola D’Ostilio

Enzo Veltri

Domenico Corsi

Ornella Garrone

Ida Paris

Giuseppina Sarobba

Francesco Giotta

Carlo Garufi

Marina Cazzaniga

Pietro Del Medico

Mario Roselli

Giuseppe Sanguineti

Isabella Sperduti

Anna Sapino

Ruggero De Maria

Carlo Leonetti

Angelo Di Leo

机构：

[1] IRCCS Regina Elena National Cancer Institute,Cellular Network and Molecular Therapeutic Target Unit

[2] IRCCS Regina Elena National Cancer Institute,Division of Medical Oncology 2

[3] IRCCS Regina Elena National CancerInstitute,Pathology Department

[4] IRCCS Regina Elena National Cancer Institute,Area of Translational Research

[5] University of Turin,Department of Medical Sciences

[6] Candiolo Cancer Institute,Medical Oncology

[7] FPO-IRCCS,Radiotherapy Unit, Department of Oncology

[8] Sandro Pertini Hospital,Medical Oncology Unit

[9] Oncology Clinic,Department of Medical, Oral and Biotechnological Sciences

[10] “Ospedali Riuniti di Ancona” Hospital,Department of Medical Oncology

[11] Careggi University Hospital,Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli

[12] St Salvatore Hospital,Department of Oncology and Hematology

[13] University Gabriele D’Annunzio,Medical Oncology Unit, A.O. Papardo & Department of Human Pathology

[14] University La Sapienza,Medical Oncology Unit, Addarii Institute of Oncology

[15] Breast Cancer Unit,Department of Oncology

[16] ASST Cremona,Medical Oncology Unit

[17] Oncology Unit,Department of Radiological, Oncological and Anatomo

[18] ASST Fatebenefratelli Sacco-PO Fatebenefratelli,Pathological Sciences

[19] University Cattolica Del Sacro Cuore,Medical Oncology

[20] University of Verona,Department of Ematology & Oncology

[21] University Hospital,Medical Oncology Unit

[22] UO Medical Oncology,Medical Oncology Unit

[23] S. Chiara Hospital,Gynaecology – Oncology Unit

[24] University of Messina,Department of Medical Oncology

[25] S. Orsola-Malpighi Hospital,Division of Medical Oncology

[26] University Campus Biomedico,Department of Systems Medicine

[27] Sant’Andrea University Hospital,Radiotherapy Department

[28] University La Sapienza,Department of Medical Oncology

[29] Umberto I University Hospital,Scientific Direction

[30] Paolo Giaccone University Hospital,undefined

[31] Pugliese-Ciaccio Hospital,undefined

[32] Medical Oncology Unit,undefined

[33] Belcolle Hospital,undefined

[34] Medical Oncology Unit,undefined

[35] Lanciano-Vasto,undefined

[36] Santa Maria Goretti Hospital,undefined

[37] Fatebenefratelli Hospital,undefined

[38] Medical Oncology AO S. Croce and Carle Teaching Hospital,undefined

[39] University Cattolica del Sacro Cuore,undefined

[40] Department of Medical Oncology,undefined

[41] ASL Nuro,undefined

[42] IRCCS Giovanni Paolo II,undefined

[43] Division of Medical Oncology,undefined

[44] Pescara Hospital,undefined

[45] Research Unit Phase I Trials and Oncology Unit,undefined

[46] ASST,undefined

[47] Reggio Calabria General Hospital,undefined

[48] Medical Oncology,undefined

[49] University Tor Vergata,undefined

[50] IRCCS Regina Elena National Cancer Institute,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 39卷

关键词：

HER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
Huang, W.
Lipton, A.
Leitzel, K.
Ali, S. M.
Fuchs, E. M.
Weidler, J.
Chappey, C.
Sperinde, J.
Tan, Y.
Jin, X.
Paquet, A.
Winston, J.
Petropoulos, C.
Kostler, W. J.
Bates, M.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
[32] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Horimoto, Yoshiya
Ishizuka, Yumiko
Ueki, Yuko
Higuchi, Toru
Arakawa, Atsushi
Saito, Mitsue
BMC CANCER, 2022, 22 (01)
[33] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Yoshiya Horimoto
Yumiko Ishizuka
Yuko Ueki
Toru Higuchi
Atsushi Arakawa
Mitsue Saito
BMC Cancer, 22
[34] Concomitant association of T-DM1 and radiation: An in vitro study on HER2 breast cancer cells
Fabien, M.
Kirova, Y.
Verrelle, P.
Teulade-Fichou, M.
Megnin-Chanet, F.
RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S597 - S598
[35] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
Vaidya, T. R.
Ait-Oudhia, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
[36] Her2 positive breast cancer: practices
Campone, Mario
Berton-Rigaud, Dominique
Bourbouloux, Emmanuelle
Sophie, Sadot
Zanetti, Alain
Frenel, Jean-Sebastien
BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
[37] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Chen, Zhaoxu
Jia, Huiqing
Zhang, Huina
Chen, Lifang
Zhao, Peng
Zhao, Jing
Fu, Guangming
Xing, Xiaoming
Li, Yujun
Wang, Chengqin
BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
[38] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Zhaoxu Chen
Huiqing Jia
Huina Zhang
Lifang Chen
Peng Zhao
Jing Zhao
Guangming Fu
Xiaoming Xing
Yujun Li
Chengqin Wang
Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
[39] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Stanowicka-Grada, Malwina
Senkus, Elzbieta
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
[40] Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
Tian, Hao
Qu, Man
Zhang, Guozhi
Yuan, Long
Shi, Qiyun
Wang, Yinhuan
Yang, Ying
Zhang, Yi
Qi, Xiaowei
ONCOLOGIST, 2023, 28 (07): : E534 - E541

← 1 2 3 4 5 →